Editas Medicine Company Profile (NASDAQ:EDIT)

About Editas Medicine

Editas Medicine logoEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDIT
  • CUSIP:
Key Metrics:
  • Previous Close: $13.54
  • 50 Day Moving Average: $16.82
  • 200 Day Moving Average: $27.58
  • 52-Week Range: $12.57 - $43.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.84
  • P/E Growth: 0.00
  • Market Cap: $479.72M
  • Outstanding Shares: 35,404,000
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 16.12%
  • Quick Ratio: 16.12%
Additional Links:
Companies Related to Editas Medicine:

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $33.75 (149.26% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetDetails
8/22/2016Jefferies GroupReiterated RatingBuyView Rating Details
5/16/2016Cowen and CompanyReiterated RatingBuyView Rating Details
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00View Rating Details
2/29/2016JPMorgan Chase & Co.Initiated CoverageNeutral$32.00View Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016        
8/9/2016Q2($0.54)($0.54)ViewListenView Earnings Details
5/16/2016Q116($0.30)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
Current Year EPS Consensus Estimate: $-2.6 EPS
Next Year EPS Consensus Estimate: $-2.8 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.44)($0.44)($0.44)
Q3 20161($0.68)($0.68)($0.68)
Q4 20161($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership Percentage: 61.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Editas Medicine (NASDAQ:EDIT)
DateHeadline
News IconSynthetic Biology Market is expected to Grow more than US$ 38 Billion by 2020 (NASDAQ:EDIT)
www.pharmiweb.com - September 29 at 9:46 AM
News IconInvestors Flock To Gene-Editing Tool, Even Though No One Knows Who Owns It Yet (NASDAQ:EDIT)
khn.org - September 23 at 4:32 PM
wsj.com logo[$$] Breakthrough Gene Technology Attracts Investors Amid Patent Dispute (NASDAQ:EDIT)
www.wsj.com - September 23 at 9:47 AM
wsj.com logoBreakthrough Gene Technology Attracts Investors Amid Patent Dispute (NASDAQ:EDIT)
www.wsj.com - September 22 at 4:51 PM
wsj.com logoBreakthrough Gene Tech Attracts Investors Amid Patent Dispute (NASDAQ:EDIT)
www.wsj.com - September 22 at 4:51 PM
News IconGene Editing: Do We Want Designer Babies? (NASDAQ:EDIT)
www.wallstreetdaily.com - September 21 at 9:03 AM
News IconBrokers Set Expectations for Editas Medicine Inc's Q2 2016 Earnings (EDIT) - DailyQuint (NASDAQ:EDIT)
dailyquint.com - September 20 at 8:30 AM
News IconEditas Medicine Inc (EDIT) Coverage Initiated at Jefferies Group - DailyQuint (NASDAQ:EDIT)
dailyquint.com - September 18 at 9:24 AM
News IconThe Way to Profit from the Biotech Story No One Is Talking About (NASDAQ:EDIT)
moneymorning.com - September 16 at 4:41 PM
4-traders.com logoADVERUM BIOTECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:EDIT)
www.4-traders.com - September 16 at 8:28 AM
News Icon2016 H2 duchenne muscular dystrophy pipeline market analysis review insights shared in detailed report (NASDAQ:EDIT)
www.whatech.com - September 12 at 4:34 PM
News Icon2016 H2 duchenne muscular dystrophy pipeline market analysis review insights shared in detailed report (NASDAQ:EDIT)
www.whatech.com - September 12 at 4:34 PM
News IconShares Lower Over the Past Quarter: Editas Medicine Inc. (NASDAQ:EDIT) - Post News (NASDAQ:EDIT)
www.kentuckypostnews.com - September 11 at 9:13 AM
News IconStock Showing Gains in Afternoon Trading: Editas Medicine Inc. (NASDAQ:EDIT) - National Daily Press (NASDAQ:EDIT)
www.nationaldailypress.com - September 10 at 9:21 AM
kcregister.com logoDon't Miss: Editas Medicine Inc. (NASDAQ:EDIT), Cempra, Inc. (NASDAQ:CEMP), Ethan Allen Interiors Inc. (NYSE:ETH ... - KC Register (NASDAQ:EDIT)
www.kcregister.com - September 10 at 9:21 AM
News IconEditas Medicine to Present at the Morgan Stanley Global Healthcare ... - EconoTimes (NASDAQ:EDIT)
www.econotimes.com - September 7 at 8:03 AM
finance.yahoo.com logoEditas Medicine to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:EDIT)
finance.yahoo.com - September 6 at 4:39 PM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial (NASDAQ:EDIT)
biz.yahoo.com - September 2 at 4:41 PM
finance.yahoo.com logoWhat Makes Editas Medicine (EDIT) a Strong Sell? - Yahoo Finance (NASDAQ:EDIT)
finance.yahoo.com - September 1 at 4:41 PM
News IconEditas Medicine Nabs Former Bristol-Myers Squibb Exec as New CSO (NASDAQ:EDIT)
www.biospace.com - August 24 at 4:42 PM
fidaily.com logoEditas Medicine, Inc. (NASDAQ:EDIT) Trading Down – Insider Trading Activity (NASDAQ:EDIT)
www.fidaily.com - August 24 at 4:42 PM
nasdaq.com logoEditas Medicine (EDIT) in Focus: Stock Moves 5.1% Higher - Nasdaq (NASDAQ:EDIT)
www.nasdaq.com - August 23 at 9:54 PM
globenewswire.com logoEditas Medicine Names Charles Albright as Chief Scientific Officer - GlobeNewswire (press release) (NASDAQ:EDIT)
globenewswire.com - August 23 at 9:54 PM
streetinsider.com logoEditas Medicine (EDIT) Names New Chief Scientific Officer - StreetInsider.com (NASDAQ:EDIT)
www.streetinsider.com - August 23 at 9:54 PM
4-traders.com logoEditas Medicine : EDIT) Names New Chief Scientific Officer (NASDAQ:EDIT)
www.4-traders.com - August 23 at 4:53 PM
streetinsider.com logoEditas Medicine (EDIT) Names New Chief Scientific Officer (NASDAQ:EDIT)
www.streetinsider.com - August 23 at 8:59 AM
publicnow.com logoEditas Medicine Names Charles Albright as Chief Scientific Officer (NASDAQ:EDIT)
www.publicnow.com - August 22 at 9:24 AM
finance.yahoo.com logoEditas Medicine (EDIT) in Focus: Stock Moves 5.1% Higher (NASDAQ:EDIT)
finance.yahoo.com - August 22 at 9:24 AM
finance.yahoo.com logoEDITAS MEDICINE, INC. Financials (NASDAQ:EDIT)
finance.yahoo.com - August 20 at 4:44 PM
News IconCRISPR takes the wraps off joint venture with Bayer (NASDAQ:EDIT)
www.bostonglobe.com - August 19 at 3:52 PM
News IconShares Moving Lower Over the Past Month Editas Medicine Inc. (NASDAQ:EDIT) - Post News (NASDAQ:EDIT)
www.kentuckypostnews.com - August 18 at 7:26 AM
fidaily.com logoEditas Medicine, Inc. (EDIT) Position Decreased by Viking Global Investors Lp Last Quarter - Finance Daily (NASDAQ:EDIT)
www.fidaily.com - August 15 at 10:14 PM
thestreet.com logoAlphabet Loses Yet Another Exec from Its 'Other Bets' Division (NASDAQ:EDIT)
www.thestreet.com - August 11 at 4:55 PM
globenewswire.com logoEditas Medicine Announces Second Quarter 2016 Results and Update - GlobeNewswire (press release) (NASDAQ:EDIT)
globenewswire.com - August 11 at 7:38 AM
biz.yahoo.com logoEditas Medicine Inc Earnings Call (Q2 2016) (NASDAQ:EDIT)
biz.yahoo.com - August 9 at 8:59 PM
globenewswire.com logoEditas Medicine Announces Second Quarter 2016 Results and Update (NASDAQ:EDIT)
globenewswire.com - August 9 at 8:59 PM
sg.finance.yahoo.com logoEditas reports 2Q loss (NASDAQ:EDIT)
sg.finance.yahoo.com - August 9 at 8:59 PM
reuters.com logoBRIEF-Adverum Biotechnologies and Editas Medicine announce collaboration - Reuters (NASDAQ:EDIT)
www.reuters.com - August 9 at 3:25 PM
nasdaq.com logoAdverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing ... - Nasdaq (NASDAQ:EDIT)
www.nasdaq.com - August 9 at 3:25 PM
News IconAdverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing ... - EconoTimes (NASDAQ:EDIT)
www.econotimes.com - August 9 at 7:37 AM
publicnow.com logoAdverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye (NASDAQ:EDIT)
www.publicnow.com - August 9 at 7:37 AM
4-traders.com logoEDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K) (NASDAQ:EDIT)
www.4-traders.com - August 8 at 4:53 PM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:EDIT)
biz.yahoo.com - August 8 at 4:53 PM
investingnews.com logoEditas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts ... - Investing News Network (press release) (registration) (blog) (NASDAQ:EDIT)
investingnews.com - August 5 at 4:48 PM
nasdaq.com logoEditas Medicine Announces Exclusive License to Advanced ... - Nasdaq (NASDAQ:EDIT)
www.nasdaq.com - August 3 at 4:53 PM
finance.yahoo.com logo8:03 am Editas Medicine enters into an exclusive license agreement with Massachusetts General Hospital to access intellectual property and technology related to Cas9 nucleases and Cas9 PAM variants (NASDAQ:EDIT)
finance.yahoo.com - August 3 at 4:53 PM
publicnow.com logoEditas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital (NASDAQ:EDIT)
www.publicnow.com - August 3 at 4:53 PM
globenewswire.com logoEditas Medicine to Host Conference Call Discussing Second Quarter 2016 Corporate Update and Results - GlobeNewswire (press release) (NASDAQ:EDIT)
globenewswire.com - August 3 at 7:46 AM
publicnow.com logoEditas Medicine to Host Conference Call Discussing Second Quarter 2016 Corporate Update and Results (NASDAQ:EDIT)
www.publicnow.com - August 2 at 4:55 PM
4-traders.com logoEditas Medicine : Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors (NASDAQ:EDIT)
www.4-traders.com - July 31 at 4:34 PM

Social

Editas Medicine (NASDAQ:EDIT) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff